Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the efficacy and safety of temozolomide in patient with relapsed or advanced anaplastic oligodendroglioma and anaplastic oligoastrocytoma.


Clinical Trial Description

Patient with relapsed or advanced anaplastic oligodendroglioma and anaplastic oligoastrocytoma will be enrolled. Enrolled patients will begin on temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days (1,000 mg/m2 per 28-day cycle). Patients who were previously treated with any chemotherapy initially received temozolomide 150 mg/m2/d for 5 days (750 mg/m2 per cycle).Patients will be receving a total 6 cycles of chemotheray (4weeks/cycle * 6cycles = 24weeks). If the patients shows responses to Temozolomide, treatment can be continued by the investigator's discretion.

During the administration of Temozolomide, vital signs, physical examination, ECOG performance status, height, weight, hematology and chemistry test, adverse events and concomitant drugs will be evaluated every four weeks. Brain MRI for tumor assessment will be performed once every 12 weeks. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01847235
Study type Interventional
Source Seoul National University Hospital
Contact
Status Completed
Phase Phase 2
Start date May 2013
Completion date March 2016

See also
  Status Clinical Trial Phase
Completed NCT01250470 - Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma Phase 1
Active, not recruiting NCT00995007 - A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas Phase 2
Completed NCT00303849 - Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors Phase 1/Phase 2
Recruiting NCT04541082 - Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms Phase 1
Completed NCT00390299 - Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme Phase 1
Completed NCT03043391 - Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children Phase 1
Recruiting NCT03975829 - Pediatric Long-Term Follow-up and Rollover Study Phase 4
Completed NCT02644291 - Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors Phase 1
Completed NCT01380782 - BIBF 1120 for Recurrent High-Grade Gliomas Phase 2
Completed NCT01082926 - Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 Phase 1
Completed NCT00362570 - Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma Phase 2
Completed NCT03434262 - SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors Phase 1
Completed NCT01316809 - AZD8055 for Adults With Recurrent Gliomas Phase 1
Recruiting NCT04135807 - Implantable Microdevice In Primary Brain Tumors Early Phase 1
Completed NCT01522820 - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Phase 1
Completed NCT00884416 - Sorafenib in Newly Diagnosed High Grade Glioma Phase 1
Active, not recruiting NCT02101905 - Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma Phase 1
Recruiting NCT05698524 - A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma Phase 1
Recruiting NCT01637753 - Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma N/A
Withdrawn NCT00734864 - Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma Phase 1